DOCK 6 Inhibitors
Chemical inhibitors of DOCK6 can modulate its function through various mechanisms that interrupt the protein's signaling pathways. NSC 23766 targets Rac1, a specific GTPase that DOCK6 acts upon as a guanine nucleotide exchange factor (GEF). By inhibiting Rac1, NSC 23766 effectively reduces DOCK6's ability to facilitate the exchange of GDP for GTP on Rac1, which is a crucial step in activating Rac1-mediated signaling pathways. Similarly, ML141 and CASIN are selective inhibitors of Cdc42, another GTPase associated with DOCK6's GEF activity. The inhibition of Cdc42 by these compounds leads to a reduction in the active, GTP-bound form of Cdc42, which in turn impedes the signaling processes that DOCK6 would typically stimulate. EHop-016 and ZCL278 also contribute to the inhibition of DOCK6 by targeting Vav2 and Cdc42's effector interactions, respectively, thereby inhibiting downstream effects of DOCK6 activation.
ITX3, by inhibiting Trio, reduces Rac1-GTP levels, which can indirectly affect DOCK6's functionality in cellular pathways where both GEFs might be active. AZA197 inhibits downstream components of the Rac1 and Cdc42 pathways such as PAK1, a kinase that acts subsequent to the GTPase activation by DOCK6. This obstruction prevents the phosphorylation events that would typically follow DOCK6's activity. Additionally, chemicals like KY02111 and RK-33 indirectly impact DOCK6 by targeting processes like Wnt signaling and β-catenin degradation, pathways in which DOCK6 has a role. Wiskostatin inhibits the N-WASP-Arp2/3 complex that is crucial for actin polymerization, a process associated with DOCK6's regulatory functions, thus indirectly diminishing DOCK6's contribution to actin cytoskeleton dynamics. Each of these chemicals interrupts the signaling cascade at various junctions that would normally be influenced by DOCK6's activity, ultimately resulting in the functional inhibition of the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
This compound inhibits Rac1, which is a GTPase that DOCK6 acts upon as a guanine nucleotide exchange factor (GEF). By inhibiting Rac1, NSC 23766 indirectly inhibits the activity of DOCK6 by preventing its substrate from transitioning to an active GTP-bound state, thereby functionally inhibiting the signaling pathways that DOCK6 would normally activate. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
ML141 is a potent and selective inhibitor of Cdc42, another GTPase that DOCK6 can potentially interact with. Inhibition of Cdc42 by ML141 would lead to a decrease in GTP-bound Cdc42 levels, which in turn would inhibit DOCK6 function, as DOCK6 would lack its active substrate to act upon. | ||||||
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $78.00 | ||
This compound is known to inhibit Vav2, a guanine nucleotide exchange factor that cooperates with DOCK6 in Rac1 activation pathways. By inhibiting Vav2, EHop-016 can decrease Rac1 activation, thus indirectly inhibiting the functional role of DOCK6 in Rac1-driven signaling processes. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 is a compound that inhibits the interaction between Cdc42 and its effector proteins. Since DOCK6 facilitates the activation of Cdc42, inhibiting the downstream effects of Cdc42 indirectly inhibits the functional outcome of DOCK6 activation. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
CASIN is a specific inhibitor of Cdc42. As with ML141, by inhibiting Cdc42, CASIN indirectly inhibits DOCK6 by reducing the pool of active substrate that DOCK6 would normally act upon, thus functionally inhibiting its role in signaling pathways. | ||||||
ITX 3 | 347323-96-0 | sc-295214 sc-295214A | 10 mg 50 mg | $145.00 $615.00 | ||
ITX3 is an inhibitor of Trio, a protein with GEF activity similar to DOCK6's GEF activity for Rac1. Inhibition of Trio by ITX3 would result in a reduction of Rac1-GTP levels, indirectly affecting DOCK6's functionality in pathways where both GEFs are operational. | ||||||
KY02111 | 1118807-13-8 | sc-397043 sc-397043A | 5 mg 25 mg | $79.00 $336.00 | ||
KY02111 promotes the degradation of β-catenin by stabilizing the destruction complex. Since DOCK6 is involved in Wnt/PCP signaling which is interconnected with β-catenin stability, the inhibition of β-catenin by KY02111 can indirectly inhibit DOCK6 function in these pathways. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
Wiskostatin is an inhibitor of the N-WASP-Arp2/3 complex, which is involved in actin polymerization. Given that DOCK6 is implicated in regulating actin cytoskeleton dynamics, potentially via N-WASP, the inhibition of this complex by Wiskostatin would indirectly inhibit the functional activity of DOCK6 in actin cytoskeleton organization. | ||||||